Paxilline treatment induced an approximately 40% decrease in combined pro-MMP-2 and MMP-2 levels in normal myoblast supernatants to levels comparable to those observed in DM1 supernatants. This evidence concerns the gene MMP2 and myotonic dystrophy type 1.